Syros Pharmaceuticals's Earnings Outlook
Portfolio Pulse from Benzinga Insights
Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to release its quarterly earnings report on March 27, 2024, with analysts expecting an EPS of $-1.14. Despite missing EPS estimates last quarter, SYRS's stock price increased by 11.76% the following day. Historically, the company's actual EPS has varied from estimates, leading to mixed stock price reactions. Shares are currently trading at $6.4, reflecting a 127.6% increase over the last 52 weeks, indicating a positive outlook from long-term shareholders.
March 26, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Syros Pharmaceuticals is expected to report an EPS of $-1.14 for the upcoming quarter. Historical performance shows mixed reactions to earnings reports, but shares have significantly appreciated over the last year.
Given the historical volatility in SYRS's stock price following earnings reports, the short-term impact is uncertain. However, the overall positive trend in the stock price over the last year and the potential for positive guidance could maintain investor interest. The importance is high due to the potential for guidance to significantly influence stock price movements.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100